Study of Vonicog Alfa for Severe Von Willebrand Disease in Children
This study is looking at how well a medicine called Vonicog Alfa (rVWF) works to prevent bleeding in children with severe Von Willebrand Disease (VWD). VWD is a condition where your blood doesn't clot properly. To join, you must be 17 years old or younger, have severe VWD, and have needed VWF concentrate treatment before. The study will treat participants with Vonicog Alfa for 12 months. Doctors will measure how many bleeding episodes you have during this time to see if the treatment is effective. The study is currently enrolling 24 participants.
- Study design
- This study is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 24 children.
- What's involved
- You will receive Vonicog Alfa by injection for 12 months. You will visit the study clinic 5 times after starting treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 12 months, which is the duration of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
At a glance
Conditions
NCT05582993
Where you'd take part
This study runs at 23 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Arnold Palmer Childrens Hosptial
Orlando, Floridastudy coordinator listed
Not yet recruiting
Bleeding and Clotting Disorders Institute
Peoria, Illinoisstudy coordinator listed
Recruiting
Children's Health Care d/b/a Children's Minnesota
Minneapolis, Minnesotastudy coordinator listed
Recruiting
Children's Health Ireland
Dublin, Irelandstudy coordinator listed
Recruiting
Childrens Hospital of Michigan
Detroit, Michiganstudy coordinator listed
Recruiting
Cure 4 the Kids
Las Vegas, Nevadastudy coordinator listed
Recruiting
Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdomstudy coordinator listed
Recruiting
Hemostase Clinique - Institut Cœur-Poumons (4eme étage aile est) Bureau 419
Lille, Francestudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Study Director · STUDY_DIRECTOR · Takeda
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Annualized Bleeding Rate (ABR) for Spontaneous or Traumatic Bleeding Episodes as Assessed by Investigator During Prophylactic Treatment With Vonicog Alfa (rVWF)12 months
ABR during the study compared to historical ABR for each participant for both spontaneous and traumatic bleeding episodes as classified by the investigator during prophylactic treatment with vonicog alfa (rVWF) will be reported.